Movano (MOVE) has commenced a blood pressure clinical trial with its newly developed cuffless blood pressure wrist wearable. The study, which is expected to be completed during the second week of February, utilizes the updated device to monitor pulse pressure waveforms in comparison with a hospital grade blood pressure device. The February 2025 study follows three clinical trials that took place in November 2024, June 2024 and October 2023 where the company used its non-invasive devices to collect pulse pressure waveform data from over 60 participants of varying gender, age, ethnicity and BMI. In mid-2025, the company plans on executing an additional 100-150 person continuous-blood pressure study using an arterial line, the results of which would help finalize the algorithm expected to be used in a future FDA pivotal trial.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MOVE:
Questions or Comments about the article? Write to editor@tipranks.com